Background The International Metastatic Renal-Cell Carcinoma Database Consortium model off ers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models.
Introduction
Treatment of metastatic renal-cell carcinoma (RCC) has been revolutionised by targeted treatments such as those directed against VEGF. This class of agents-which includes sunitinib, 1 sorafenib, 2 bevacizumab, 3,4 pazopanib, 5 and axitinib 6 -has been included in treatment for patients with this advanced disease. The new era of targeted treatment needs new prognostic models and updated survival data for accurate clinical trial design, patient counselling, and risk-specifi c treatment. Thus, the International Metastatic RCC Database Consortium 7, 8 derived the fi rst prognostic model since the development of targeted treatment from a large multicentre cohort. Six independent predictors of poor survival were identifi ed: Karnofsky performance status of less than 80%, less than 1 year from diagnosis to treatment, anaemia (haemoglobin concentration <lower limit of normal), hypercalcaemia (corrected calcium concentration >upper limit of normal), neutrophilia (neutrophil count >upper limit of normal), and thrombocytosis (platelet count >upper limit of normal). According to the number of poor prognostic factors, patients were segregated into favourable (no factors), intermediate (one or two factors), and poor (more than three factors) risk groups.
Other prognostic models for metastatic RCC exist but are based on outcomes of patients treated with immunotherapy or on single-institution experiences (table 1). The most widely used system is the Memorial Sloan-Kettering Cancer Center (MSKCC) model, 13 which contains many of the same factors as the Database Consortium model. Other models include the Cleveland Clinic Foundation (CCF) model, 9 the updated French model adapted to the AVOREN trial, 10, 11 and the International Kidney Cancer Working Group (IKCWG) model. 12 An ideal prognostic model is easy to use, includes only the most relevant patient and disease characteristics, and is able to accurately distinguish between groups of patients with diff erent outcomes. We tested the validity of the metastatic RCC Database Consortium model in a large international multicentre dataset and compared its accuracy with other prognostic models.
Methods

Participants
In this population-based analysis, we included consecutive patients from 13 international cancer centres (fi ve in the USA, fi ve in Canada, one in South Korea, one in Singapore, and one in Denmark). The 645 patients originally used 7 to derive the Database Consortium model were not included in this analysis. We collected data between Aug 15, 2008, and Jan 14, 2011. Included patients had metastatic RCC treated between 2004 and 2010 with an anti-VEGF targeted treatment (sunitinib, sorafenib, bevacizumab, axitinib, or pazopanib) as their fi rst anti-VEGF agent. Previous immunotherapy was allowed (ie, targeted treatment as second-line treatment). Patients treated with front-line mTOR inhibitors were excluded.
We collected baseline patient characteristics and outcome data with uniform data collection templates as described previously. 7 Laboratory test results were standardised against institutional upper limit of normal and lower limit of normal values when appropriate. The study was approved by the institutional review board at each participating centre.
Statistical analysis
The primary endpoint was overall survival, defi ned as the time from start of targeted treatment to death or censored at date of last follow-up. We assessed the predictive accuracy of the model by the concordance index, 14 which is the area under the receiver operating curve for survival time in the presence of censored data. A concordance index of 0·5 represents no predictive discrimination and an index of 1 represents perfect ability to distinguish patients. We classifi ed patients into risk groups with four other existing prognostic models (CCF, French, IKCWG, and MSKCC; table 1) and fi tted them into Cox regressions for overall survival. Each of these models was compared to the Database Consortium model with: (1) Bayes information criterion, a global measure of model fi t in which a low number represents a good fi t; (2) generalised R 2 , a statistic between 0 and 1 that is large when the covariates are strongly associated with the dependent variable; 15 and (3) the concordance index.
We also compared performance between models with new measures based on reclassifi cation of risk categories-ie, reclassifi cation calibration 16 and net reclassifi cation improvement. 17 These measures are based on a cross-tabulation comparing the Database Consortium model with the others. The 3 × 3 table of the risk groups (favourable, intermediate, and poor) for the two models in each comparison provides nine groups. For each group, we compared the reported number of events from Kaplan-Meier estimates with the predicted number of events from Cox regression at 2 years after start of treatment with the following formulas:
Reported number of deaths = number of patients in the group × 2-year death rate for that group estimated by Kaplan-Meier method Predicted number of deaths = number of patients in that group × predicted 2-year risk rate for the risk group according to the model These calculations generate two reclassifi cation calibration χ² statistics: the model with the smaller χ² has a better fi t (K -2 degrees of freedom, where K is the number of cells with at least 20 observations).
For the net reclassifi cation improvement analysis, the 3 × 3 tables were further stratifi ed by patient survival status at 2 years after the start of treatment. We calculated the proportions of participants who were classifi ed into diff erent risk groups (either a better or worse risk group) in each model separately for dead and alive patients. Patients who had not reached 2 years of follow-up were excluded from this analysis.
Net reclassifi cation improvement = (prob(worse risk group/died) -prob(better risk group/died)) + (prob(better risk group/alive) -prob(worse risk group/alive)) Thus, a higher net reclassifi cation improvement means that a model had a better reclassifi cation compared with the other model-ie, the model is more likely to classify dead patients to a poor risk group or alive patients to a favourable risk group.
We used multiple imputation to account for missing data. 18 Unlike single imputation methods, multiple imputation yields several plausible imputed datasets to account for the uncertainty caused by missing data. These multiple-imputed datasets are then analysed by using standard procedures for complete data and combining the results obtained from each. For this analysis, fi ve imputation datasets for missing data were created with the ice package of Stata (version 11) to ensure that results were consistent when compared with the complete case analyses. Each imputation dataset was analysed with the same methods as from the original dataset without imputation. Rubin's rules 19 were used to combine results from the fi ve imputation datasets, by computing the mean of the fi ve estimates and a variance estimate that includes components for both within-imputation and across-imputation for each measurement of model fi t when appropriate. Sample sizes were determined by the size of consecutive cohorts of patients from each centre. We report results from the complete case analysis in this report and results from the imputation datasets are included in the appendix. Statistical computations were done with SAS (version 9.2) and R (version 2.12). Reclassifi cation measures were done with SAS Macros implemented by Cook 
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Results
1028 patients were eligible for this analysis. At the cutoff date, 851 patients (83%) had discontinued targeted treatment and 447 (43%) were alive. Median follow-up in those alive was 16·3 months (IQR 7·4-30·6) and the median overall survival of all patients was 18·8 months (95% CI 17·6-21·4). Table 2 shows baseline characteristics. Because data were missing for some laboratory measurements, only 849 patients (83%) had complete data for the Database Consortium model and 672 (65%) had complete data for all fi ve models. In multivariable analysis for the Database Consortium model, the six risk factors were independent predictors of poor overall survival (hazard ratios [HRs] ranged from 1·27 to 2·08; table 3 ). The HRs in the validation dataset were much the same as those in the original model, which suggests excellent external validation. 157 of 849 (18%) patients were in the favourable risk group and had a median overall survival of 43·2 months (95% CI 31·4-50·1. 440 patients (52%) were in the intermediate risk group and had a median overall survival of 22·5 months (95% CI 18·7-25·1). 252 patients (30%) were in the poor risk group and had a median overall survival of 7·8 months (95% CI 6·5-9·7). Figure 1 shows clear distinctions between risk groups (log rank p<0·0001). The concordance index of this model was 0·71 (95% CI 0·68-0·73) using the individual risk factors and 0·66 (0·64-0·69) when using the three risk groups.
Only the 672 patients with complete data for all fi ve prognostic models were included in the comparison between the Database Consortium model and other models. We calculated concordance indices for each model (table 4) . The indices were similar for all models except for the French model, which was slightly lower than the others. Other measures of fi t showed that the Database Consortium model was not inferior to other models. Bayes information criterion was lowest for the Database Consortium model, suggesting that this model had the best fi t and the generalised R² was the highest, suggesting that this model was most strongly associated with outcomes (table 4) .
We included analysis with new measures of fi t, including the reclassifi cation calibration test. This statistic is formed on the comparison of two models. In this case, nine groups from the 3 × 3 cross-tabulation of the two models were evaluated (x-axes of fi gure 2). For 
Haemoglobin concentration <lower limit of normal 1·72 (1·31-2·26) 0·0001 1·69 (1·38-2·06) <0·0001
Calcium concentration >upper limit of normal 1·81 (1·29-2·53) 0·0006 1·45 (1·10-1·92) 0·0087
Neutrophil count >upper limit of normal 2·42 (1·72-3·39) <0·0001 1·64 (1·31-2·05) <0·0001
Platelet count >upper limit of normal
The concordance index of the original model was 0·73. For the validation group it was 0·71 (95% CI 0·68-0·73). KPS=Karnofsky performance status. *From multivariable Cox regression. According to net reclassifi cation improvement (fi gure 3), the Database Consortium model reclassifi ed patients more correctly than did the French model (by 23%) and the MSKCC model (by 10%). We did not detect a signifi cant improvement compared with the IKCWG model. The CCF model reclassifi ed 13% of patients more correctly but had a lower concordance index than did the Database Consortium model. Although the CCF model improved classifi cation by net reclassifi cation improvement in the fi rst 2 years, no diff erence existed at 3 and 4 years (net reclassifi cation improvement was 6% at 3 years and -1% at 4 years; p>0·05). By contrast, the Database Consortium model classifi ed patients to the correct risk group better than did the French model at 3 and 4 years (data not shown).
We used fi ve imputation datasets to account for missing data in clinical covariates. The aggregated results across fi ve imputation datasets had similar concordance indices, reclassifi cation calibration, and net reclassifi cation improvement compared with complete case analyses (appendix).
Discussion
To our knowledge, this study is the largest external validation and comparison of prognostic models for metastatic RCC (panel). This study externally validates the International Metastatic RCC Database Consortium model. This study also provides clinicians with long-term overall survival data, which can be used for more accurate prognosis, patient counselling, and clinical trial design. A median overall survival of 43 months after the start of targeted treatment in the favourable risk group has set a new benchmark for this disease and is a testament to the
Data are death rate (95% CI). CCF=Cleveland Clinic Foundation. IKCWG=International Kidney Cancer Working Group. MSKCC=Memorial Sloan-Kettering Cancer Center. DCM=Database Consortium model. , and the MSKCC model (D), calculated according to patient's survival status at 2 years after start of anti-VEGF targeted treatment. 489 patients were included, of whom 161 were alive and 328 were dead. 183 who had not reached 2 years follow-up were excluded. As an example, comparing the French model with the DCM, 14% of alive patients were incorrectly moved to a worse risk group and 36% were correctly moved to a better risk group by the DCM, resulting in a 22% (36% -14%) improvement. 17% of patients who had died were correctly moved to a worse risk group and 16% were incorrectly moved to a better risk group by DCM, resulting in a 1% (17% -16%) improvement. effi cacy of targeted treatment. These survival results might be more generalisable to our clinic populations than are clinical trial data since the Database Consortium criteria are based on an unselected, consecutive series of patients. 20 The comparisons of fi t showed that diff erent models can yield dissimilar prognosis on the basis of inclusion of diff erent clinical factors. Overall, the concordance indices, aside from that of the French model, are within a similar range. Also, more complex models-eg, the IKCWG model, which includes mathematical transformations and more clinical factors-might not add signifi cantly more accuracy or discriminatory power once simplifi ed into three risk groups. The Database Consortium model has a high accordance of risk groups with MSKCC, except that 14% of the population was upgraded to a less favourable risk group by the Database Consortium model. By upgrading these patients to a higher risk (ie, from MSKCC intermediate to Database Consortium model poor), the model showed better fi t and reclassifi cation accuracy by both reclassifi cation calibration and net reclassifi cation improvement (fi gures 2D, 3D).
With at least fi ve clinical prognostic nomograms for metastatic RCC, the use of clinical factors for prognosis has probably reached a limit. We use these models because they are the best available. Other models with similar concordance indices have been published for hepatocellular carcinoma 21 and prostate cancer. 22 The discriminatory ability of the Database Consortium model might be improved by using individual risk factors instead of collapsing them into three risk categories. The addition of tumour-specifi c or patient-specifi c biomarkers is the next likely step for improvement of the accuracy of these models. Angiogenesis biomarkers could add prognostic information for overall survival but need external validation. 23 Biomarkers related to germline polymorphisms might be another useful non-clinical factor for prognosis. For example, a study of 136 patients with clear-cell metastatic RCC treated with sunitinib reported a potentially favourable genetic profi le. This profi le included an A allele in the CYP3A5 6986A/G loci, a missing CAT copy in the NR1/3 haplotype, and a TCG copy in the ABCB1 haplotype. Patients with this profi le had improved progression-free and overall survival compared with patients without. 24 In the future, incorporation of these potential biomarkers into the Database Consortium model might improve prognostic accuracy.
Strengths of this study are that it is generalisable and the sample size of previously unanalysed patients was large. We included patients who were treated in clinical trials, off protocol, in academic centres, in community centres, in several countries, and with all RCC histologies. Additionally, modern targeted treatment was used to treat these patients as determined by normal practice at each institution. Thus, these results represent treatment of metastatic RCC in the modern era in which physicians and patients have several treatment options and are not limited to only immunotherapy. This work also expands on early experience, when access to targeted treatments was limited.
Limitations of this retrospective analysis include missing data. We used multiple imputation datasets to account for missing data and they yielded similar results. Additionally, the amount of missing data in all data elements was less than 5% and results were similar between the complete case analyses and the analyses using imputed data for missing values. Finally, comparisons between diff erent fi rst-line drugs are diffi cult to do because this dataset included patients mainly treated with sunitinib and sorafenib. However, we have shown that this model is not aff ected by fi rstline drug choice. 7 Now externally validated, the International Metastatic RCC Database Consortium model can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis. This model might be better than others with respect to ease of use and stratifi cation capability.
Patient-specifi c and tumour-specifi c biomarkers that can predict response and prognosis should be investigated.
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Panel: Research in context
Systematic review A Medline search for "metastatic renal cell carcinoma", "prognostic factors", and "external validation" yielded no articles that externally validated or compared the Database Consortium model to other models available for metastatic renal-cell carcinoma. The Database Consortium model was developed as a prognosis model for patients with metastatic renal-cell carcinoma treated in the era of targeted treatment.
Interpretation
This study externally validates the Database Consortium model in a new dataset of patients with metastatic renal-cell carcinoma treated with targeted treatment. As a result, this model can be used in clinical practice for patient counselling and risk stratifi cation in clinical trials. A comparison of existing models shows that a ceiling in prognosis has been reached using clinical variables alone. Thus, biomarkers or other prognostic factors that can be added to these criteria should be investigated.
